鉴定与tigecycline相关的低纤维素生成性病的危险因素和预测指标
Xiaohui Liu1, Xuefeng Yuan2, Long Wen3
1Department of Pharmacy, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, China.
Clinical and translational science
|April 4, 2025
概括
提格环素的使用可能会导致低纤维素生成血症,这是一种影响血液凝固的疾病. 高剂量和直接胆红素的升高是危险因素,而基线纤维素素水平提供保护.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 临床医学 临床医学
背景情况:
- 提格环素是一种用于复杂感染的抗生素.
- 纤维素原水平下降的低纤维素原血症可以破坏凝血.
- 提格环素使用与低纤维素生成血症之间的关系需要研究.
研究的目的:
- 为了确定在接受tigecycline的患者中低纤维素生成血的患病率.
- 为了确定与tigecycline诱导的低纤维素生成血症相关的临床表现和危险因素.
- 为临床实践提供有关监测和管理的信息.
主要方法:
- 在50名成年患者的观察性研究中,用tigecycline治疗超过48小时.
- 患者被划分为低纤维素生成血症 (<2.0 g/L纤维素) 和正常组.
- 多变量逻辑回归分析了低纤维素生成血的危险因素.
主要成果:
- 在50名患者中,有24名患者出现过低纤维素生成血症.
- 记录了三起胃肠道出血事件和四起需要纤维素原剂的病例.
- 风险因素包括较高的环素总剂量 (OR=15.28) 和基线直接胆红素>0.4 mg/dL (OR=5.79).
- 基线纤维素水平是一个保护因素 (OR=0.53).
结论:
- 提格环素的使用与低纤维素生成血症和潜在的不良事件有关.
- 医疗保健提供者应监测接受tigecycline的患者的凝血.
- 对于肝功能障碍,基线纤维素素低,直接胆红素升高或高累积剂量患者,需要特别警.
相关概念视频
Factors Affecting the Risk of Infection
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.


